ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

DCE Advisors approver New Grant Programs In Ovarian Cancer, Biostatistics, Biotech Transfer; Support Services Recompetitions

June 19, 1992

BMS Settles Charges Of Obstructing Generics

March 14, 2003

Retraction Based On Data Given To Duke Last November, But Apparently Disregarded

October 29, 2010

Clearinghouse Agrees: Three Dyes, Hair Color Agent Are Carcinogens; Risk To Humans – Brown

May 5, 1978

Where’s The Money for Local Programs? Everyone Wants To Know

February 28, 1975

Tamoxifen Offers Long-Term Benefits For Prevention

March 30, 2007